Beijing Tri Prime Gene Pharmaceutical Co (BJSE:837344) ROCE % : 1.47% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Beijing Tri Prime Gene Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beijing Tri Prime Gene Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 1.47%.

Beijing Tri Prime Gene Pharmaceutical Co ROCE % Historical Data

The historical data trend for Beijing Tri Prime Gene Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Tri Prime Gene Pharmaceutical Co ROCE % Chart

Beijing Tri Prime Gene Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

24.97

9.72

8.37

3.70

4.05

Beijing Tri Prime Gene Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															1.11	4.20	0.63	9.34	1.47

Beijing Tri Prime Gene Pharmaceutical Co ROCE % Calculation

Beijing Tri Prime Gene Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	38.139	/	( ( (933.632 - 125.554)	+	(1235.174 - 160.349) )	/ 2 )
	=	38.139	/	( (808.078	+	1074.825)	/ 2 )
	=	38.139	/	941.4515
	=	4.05 %

Beijing Tri Prime Gene Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	15.932	/	( ( (1235.174 - 160.349)	+	(1221.289 - 124.149) )	/ 2 )
	=	15.932	/	( ( 1074.825	+	1097.14 )	/ 2 )
	=	15.932	/	1085.9825
	=	1.47 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Beijing Tri Prime Gene Pharmaceutical Co (BJSE:837344) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beijing Tri Prime Gene Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Beijing Tri Prime Gene Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Tri Prime Gene Pharmaceutical Co (BJSE:837344) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Tri Prime Gene Pharmaceutical Co Ltd (BJSE:837344) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Jinyuan Road, Building 4, Daxing Economic Development Zone, Daxing District, Beijing, CHN, 102600

Website

http://www.triprime.com

Beijing Tri Prime Gene Pharmaceutical Co Ltd is mainly engaged in the research, development, production, and sales of medical biotechnology products including genetic engineering drugs, genetic engineering vaccines, and diagnostic reagents, and engaged in related technical trade and technical consulting services. Its product line comprises Yundex Spray, Yundex Eye Drops, Yundexol Powder Injection, Yundexol Water Injection.

Beijing Tri Prime Gene Pharmaceutical Co (BJSE:837344) Headlines

No Headlines